Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years.
CRISPR
Cancer
Cardiovascular
Diagnosis
Display techniques
Infectious-disease
Nanobody
Nanobody-imaging
Neurogenerative
Neurogenerative diseases
Production
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
received:
19
06
2024
accepted:
03
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
Nanobodies (Nbs) are antibody fragments derived from heavy-chain-only IgG antibodies found in the Camelidae family as well as cartilaginous fish. Their unique structural and functional properties, such as their small size, the ability to be engineered for high antigen-binding affinity, stability under extreme conditions, and ease of production, have made them promising tools for diagnostics and therapeutics. This potential was realized in 2018 with the approval of caplacizumab, the world's first Nb-based drug. Currently, Nbs are being investigated in clinical trials for a broad range of treatments, including targeted therapies against PDL1 and Epidermal Growth Factor Receptor (EGFR), cardiovascular diseases, inflammatory conditions, and neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. They are also being studied for their potential for detecting and imaging autoimmune conditions and infectious diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A variety of methods are now available to generate target-specific Nbs quickly and efficiently at low costs, increasing their accessibility. This article examines these diverse applications of Nbs and their promising roles. Only the most recent articles published in the last five years have been used to summarize the most advanced developments in the field.
Identifiants
pubmed: 39455963
doi: 10.1186/s12951-024-02900-y
pii: 10.1186/s12951-024-02900-y
doi:
Substances chimiques
Single-Domain Antibodies
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
661Informations de copyright
© 2024. The Author(s).
Références
Kang W, et al. Nanobody conjugates for targeted cancer therapy and imaging. Technol Cancer Res Treat. 2021;20:15330338211010116.
pubmed: 33929911
pmcid: 8111546
doi: 10.1177/15330338211010117
Kunz S, et al. NANOBODY((R)) molecule, a giga medical tool in nanodimensions. Int J Mol Sci. 2023;24(17):13229.
pubmed: 37686035
pmcid: 10487883
doi: 10.3390/ijms241713229
Jin BK, et al. NANOBODIES®: a review of diagnostic and therapeutic applications. Int J Mol Sci. 2023;24(6):5994.
pubmed: 36983063
pmcid: 10057852
doi: 10.3390/ijms24065994
Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–97.
pubmed: 23495938
doi: 10.1146/annurev-biochem-063011-092449
Salvador JP, Vilaplana L, Marco MP. Nanobody: outstanding features for diagnostic and therapeutic applications. Anal Bioanal Chem. 2019;411(9):1703–13.
pubmed: 30734854
doi: 10.1007/s00216-019-01633-4
De Genst E, et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci. 2006;103(12):4586–91.
pubmed: 16537393
pmcid: 1450215
doi: 10.1073/pnas.0505379103
Mitchell LS, Colwell LJ. Analysis of nanobody paratopes reveals greater diversity than classical antibodies. Protein Eng Des Sel. 2018;31(7–8):267–75.
pubmed: 30053276
pmcid: 6277174
doi: 10.1093/protein/gzy017
Jovcevska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs. 2020;34(1):11–26.
pubmed: 31686399
doi: 10.1007/s40259-019-00392-z
Ruiz-López E, Schuhmacher AJ. Transportation of single-domain antibodies through the blood–brain barrier. Biomolecules. 2021;11(8):1131.
pubmed: 34439797
pmcid: 8394617
doi: 10.3390/biom11081131
Wang Y, et al. Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications. Int J Nanomedicine. 2016;11:3287–303.
pubmed: 27499623
pmcid: 4959585
doi: 10.2147/IJN.S107194
Lin J, et al. A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics. PLoS ONE. 2021;16(7): e0254944.
pubmed: 34297759
pmcid: 8301669
doi: 10.1371/journal.pone.0254944
Muyldermans S. A guide to: generation and design of nanobodies. FEBS J. 2021;288(7):2084–102.
pubmed: 32780549
doi: 10.1111/febs.15515
Sinclair L, et al. Microbial community composition and diversity via 16S rRNA gene amplicons: evaluating the illumina platform. PLoS ONE. 2015;10(2): e0116955.
pubmed: 25647581
pmcid: 4315398
doi: 10.1371/journal.pone.0116955
Drengenes C, et al. Exploring protocol bias in airway microbiome studies: one versus two PCR steps and 16S rRNA gene region V3 V4 versus V4. BMC Genomics. 2021;22(1):3.
pubmed: 33397283
pmcid: 7784388
doi: 10.1186/s12864-020-07252-z
Eisenstein M. Microbiology: making the best of PCR bias. Nat Methods. 2018;15(5):317–20.
pubmed: 29702634
doi: 10.1038/nmeth.4683
Teymennet-Ramírez KV, Martínez-Morales F, Trejo-Hernández MR. Yeast surface display system: strategies for improvement and biotechnological applications. Front Bioeng Biotechnol. 2022; 9.
Kolmar H, et al. Construction of semisynthetic shark vNAR yeast surface display antibody libraries. Methods Mol Biol. 2023;2702:227–43.
pubmed: 37679622
doi: 10.1007/978-1-0716-3381-6_11
Takeda H, et al. VNAR development through antigen immunization of Japanese topeshark (Hemitriakis japanica). Front Bioeng Biotechnol. 2023; 11.
Valdés-Tresanco MS, et al. Structural insights into the design of synthetic nanobody libraries. Molecules. 2022;27(7):2198.
pubmed: 35408597
pmcid: 9000494
doi: 10.3390/molecules27072198
Moreno E, et al. Structure-based design and construction of a synthetic phage display nanobody library. BMC Res Notes. 2022;15(1):124.
pubmed: 35351202
pmcid: 8966178
doi: 10.1186/s13104-022-06001-7
Murakami T, et al. Construction of a humanized artificial VHH library reproducing structural features of camelid VHHs for therapeutics. Antibodies (Basel). 2022;11(1):10.
pubmed: 35225868
doi: 10.3390/antib11010010
Contreras MA, et al. Design and construction of a synthetic nanobody library: testing its potential with a single selection round strategy. Molecules. 2023;28(9):3708.
pubmed: 37175117
pmcid: 10180287
doi: 10.3390/molecules28093708
Asaadi Y, et al. A comprehensive comparison between camelid nanobodies and single chain variable fragments. Biomarker Research. 2021;9(1):87.
pubmed: 34863296
pmcid: 8642758
doi: 10.1186/s40364-021-00332-6
Tsukahara N, et al. An alpaca single-domain antibody (VHH) phage display library constructed by CDR shuffling provided high-affinity VHHs against desired protein antigens. Int Immunol. 2022;34(8):421–34.
pubmed: 35689594
doi: 10.1093/intimm/dxac022
Liu B, Yang D. Easily established and multifunctional synthetic nanobody libraries as research tools. Int J Mol Sci. 2022;23(3):1482.
pubmed: 35163405
pmcid: 8835997
doi: 10.3390/ijms23031482
Salema V, Fernandez LA. Escherichia coli surface display for the selection of nanobodies. Microb Biotechnol. 2017;10(6):1468–84.
pubmed: 28772027
pmcid: 5658595
doi: 10.1111/1751-7915.12819
Uchanski T, et al. An improved yeast surface display platform for the screening of nanobody immune libraries. Sci Rep. 2019;9(1):382.
pubmed: 30674983
pmcid: 6344588
doi: 10.1038/s41598-018-37212-3
Rossotti MA, et al. Isolation and characterization of single-domain antibodies from immune phage display libraries. Methods Mol Biol. 2023;2702:107–47.
pubmed: 37679618
doi: 10.1007/978-1-0716-3381-6_7
McMahon C, et al. Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nat Struct Mol Biol. 2018;25(3):289–96.
pubmed: 29434346
pmcid: 5839991
doi: 10.1038/s41594-018-0028-6
Wu X, Zhang J, Fang L. Next-generation sequencing and proteomics-enabled approach for rapid and high-throughput isolation of virus-neutralizing Nanobodies. In: Lozach P-Y, editor. Rift valley fever virus: methods and protocols. New York: Springer, US; 2024. p. 135–46.
doi: 10.1007/978-1-0716-3926-9_10
Zhao Y, et al. Construction of synthetic nanobody library in mammalian cells by dsDNA-based strategies*. ChemBioChem. 2021;22(20):2957–65.
pubmed: 34411391
doi: 10.1002/cbic.202100286
Pardon E, et al. A general protocol for the generation of Nanobodies for structural biology. Nat Protoc. 2014;9(3):674–93.
pubmed: 24577359
pmcid: 4297639
doi: 10.1038/nprot.2014.039
Egloff P, et al. Engineered peptide barcodes for in-depth analyses of binding protein libraries. Nat Methods. 2019;16(5):421–8.
pubmed: 31011184
pmcid: 7116144
doi: 10.1038/s41592-019-0389-8
Dufner P, Jermutus L, Minter RR. Harnessing phage and ribosome display for antibody optimisation. Trends Biotechnol. 2006;24(11):523–9.
pubmed: 17000017
doi: 10.1016/j.tibtech.2006.09.004
Omidfar K, Daneshpour M. Advances in phage display technology for drug discovery. Expert Opin Drug Discov. 2015;10(6):651–69.
pubmed: 25910798
doi: 10.1517/17460441.2015.1037738
Fu Y, et al. A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike. PLoS ONE. 2022;17(8): e0272364.
pubmed: 35947606
pmcid: 9365158
doi: 10.1371/journal.pone.0272364
Grahn AK, Allen GL, Kay BK. Efficient cloning of inserts for phage display by golden gate assembly. Methods Mol Biol. 2023;2702:191–203.
pubmed: 37679620
doi: 10.1007/978-1-0716-3381-6_9
Lim HT, et al. Exploring shark VNAR antibody against infectious diseases using phage display technology. Fish Shellfish Immunol. 2023;140: 108986.
pubmed: 37541634
doi: 10.1016/j.fsi.2023.108986
Nakazawa H, et al. Synthesis of epitope-targeting nanobody based on native protein-protein interactions for FtsZ filamentation suppressor. Biotechnol J. 2023;18(11): e2300039.
pubmed: 37458140
doi: 10.1002/biot.202300039
Sellmann C, et al. A one-step process for the construction of phage display scFv and VHH libraries. Mol Biotechnol. 2020;62(4):228–39.
pubmed: 31981039
doi: 10.1007/s12033-020-00236-0
Koide A, Koide S. Affinity maturation of single-domain antibodies by yeast surface display. Methods Mol Biol. 2012;911:431–43.
pubmed: 22886267
doi: 10.1007/978-1-61779-968-6_26
Roth L, et al. Isolation of antigen-specific VHH single-domain antibodies by combining animal immunization with yeast surface display. Methods Mol Biol. 2020;2070:173–89.
pubmed: 31625096
doi: 10.1007/978-1-4939-9853-1_10
Sun Y, et al. A fine-tuned yeast surface-display/secretion platform enables the rapid discovery of neutralizing antibodies against Clostridioides difficile toxins. Microb Cell Fact. 2023;22(1):194.
pubmed: 37749574
pmcid: 10519002
doi: 10.1186/s12934-023-02200-4
Gaiotto T, et al. Nanobodies mapped to cross-reactive and divergent epitopes on A(H7N9) influenza hemagglutinin using yeast display. Sci Rep. 2021;11(1):3126.
pubmed: 33542302
pmcid: 7862619
doi: 10.1038/s41598-021-82356-4
Ming K, et al. Development of nanobodies against Staphylococcus enterotoxin B through yeast surface display. Int J Biol Macromol. 2023;253: 126822.
pubmed: 37703983
doi: 10.1016/j.ijbiomac.2023.126822
Fleetwood F, et al. Surface display of a single-domain antibody library on Gram-positive bacteria. Cell Mol Life Sci. 2013;70(6):1081–93.
pubmed: 23064703
doi: 10.1007/s00018-012-1179-y
Cavallari M. Rapid and direct VHH and target identification by staphylococcal surface display libraries. Int J Mol Sci. 2017;18(7):1507.
pubmed: 28704956
pmcid: 5535997
doi: 10.3390/ijms18071507
Hanes J, Jermutus L, Pluckthun A. Selecting and evolving functional proteins in vitro by ribosome display. Methods Enzymol. 2000;328:404–30.
pubmed: 11075357
doi: 10.1016/S0076-6879(00)28409-7
Wang H, Liu R. Advantages of mRNA display selections over other selection techniques for investigation of protein-protein interactions. Expert Rev Proteomics. 2011;8(3):335–46.
pubmed: 21679115
doi: 10.1586/epr.11.15
Ferrari D, et al. A novel nanobody scaffold optimized for bacterial expression and suitable for the construction of ribosome display libraries. Mol Biotechnol. 2020;62(1):43–55.
pubmed: 31720928
doi: 10.1007/s12033-019-00224-z
Madigan V, Zhang F, Dahlman JE. Drug delivery systems for CRISPR-based genome editors. Nat Rev Drug Discov. 2023;22(11):875–94.
pubmed: 37723222
doi: 10.1038/s41573-023-00762-x
Landberg J, et al. CRISPR interference of nucleotide biosynthesis improves production of a single-domain antibody in Escherichia coli. Biotechnol Bioeng. 2020;117(12):3835–48.
pubmed: 32808670
pmcid: 7818426
doi: 10.1002/bit.27536
Mo F, et al. Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy. Signal Transduct Target Ther. 2021;6(1):80.
pubmed: 33627635
pmcid: 7904846
doi: 10.1038/s41392-021-00462-1
Deng C, et al. Split-Cas9-based targeted gene editing and nanobody-mediated proteolysis-targeting chimeras optogenetically coordinated regulation of Survivin to control the fate of cancer cells. Clin Transl Med. 2023;13(8): e1382.
pubmed: 37620295
pmcid: 10449816
doi: 10.1002/ctm2.1382
Cross FR, et al. Expanding and improving nanobody repertoires using a yeast display method: targeting SARS-CoV-2. J Biol Chem. 2023; 299(3).
Hambach J, et al. Targeting CD38-expressing multiple myeloma and burkitt lymphoma cells in vitro with nanobody-based chimeric antigen receptors (Nb-CARs). Cells. 2020;9(2):321.
pubmed: 32013131
pmcid: 7072387
doi: 10.3390/cells9020321
Hambach J, et al. Half-life extended nanobody-based CD38-specific bispecific killercell engagers induce killing of multiple myeloma cells. Front Immunol. 2022;13: 838406.
pubmed: 35651607
pmcid: 9150782
doi: 10.3389/fimmu.2022.838406
Hosseininejad-Chafi M, et al. Development of a functional nanobody targeting programmed cell death protein-1 as immune checkpoint inhibitor. Curr Pharm Des. 2023;29(29):2336–44.
pubmed: 37859326
doi: 10.2174/0113816128258475230920054122
Bitsch P, et al. Penetration of nanobody-dextran polymer conjugates through tumor spheroids. Pharmaceutics. 2023;15(10):2374.
pubmed: 37896133
pmcid: 10609859
doi: 10.3390/pharmaceutics15102374
Deken MM, et al. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. J Control Release. 2020;323:269–81.
pubmed: 32330574
pmcid: 7116241
doi: 10.1016/j.jconrel.2020.04.030
Barough MS, et al. Anti–MUC1 nanobody can synergize the Tamoxifen and Herceptin effects on breast cancer cells by inducing ER, PR and HER2 overexpression. Int Immunopharmacol. 2023;124: 110792.
doi: 10.1016/j.intimp.2023.110792
Liu X, et al. A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells. Front Immunol. 2023;14:1292839.
pubmed: 37954614
pmcid: 10634241
doi: 10.3389/fimmu.2023.1292839
Arvindam US, et al. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia. 2021;35(6):1586–96.
pubmed: 33097838
doi: 10.1038/s41375-020-01065-5
Fan X, et al. Optimized silk fibroin nanoparticle functionalization with anti-CEA nanobody enhancing active targeting of colorectal cancer cells. Biomed Mater. 2023; 18(4).
Le Tourneau C, et al. Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors. ESMO Open. 2022;7(5): 100576.
pubmed: 36108560
pmcid: 9588896
doi: 10.1016/j.esmoop.2022.100576
Roshan R, et al. Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy. Mol Immunol. 2021;129:70–7.
pubmed: 33183767
doi: 10.1016/j.molimm.2020.10.021
Nasiri F, Safarzadeh Kozani P, Rahbarizadeh F. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts. Front Immunol. 2023;14:1063838.
pubmed: 36875091
pmcid: 9978144
doi: 10.3389/fimmu.2023.1063838
Vaneycken I, et al. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/Micro-CT. J Nucl Med. 2010;51(7):1099–106.
pubmed: 20554727
doi: 10.2967/jnumed.109.069823
Khirehgesh MR, et al. Design and construction a novel humanized biparatopic nanobody-based immunotoxin against epidermal growth factor receptor (EGFR). J Drug Delivery Sci Technol. 2021;66: 102837.
doi: 10.1016/j.jddst.2021.102837
Zhu X-Y, et al. A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity. Acta Pharmacol Sin. 2024;45(3):609–18.
pubmed: 38030799
doi: 10.1038/s41401-023-01200-9
Bao C, et al. The application of nanobody in CAR-T therapy. Biomolecules. 2021;11(2):238.
pubmed: 33567640
pmcid: 7914546
doi: 10.3390/biom11020238
Safarzadeh Kozani P, et al. Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res. 2022;10(1):24.
pubmed: 35468841
pmcid: 9036779
doi: 10.1186/s40364-022-00371-7
Zhang M, et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma. Clin Cancer Res. 2022;28(13):2830–43.
pubmed: 35435984
doi: 10.1158/1078-0432.CCR-21-4097
Xia B, et al. Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment. Mol Ther Oncolytics. 2023;30:86–102.
pubmed: 37593111
pmcid: 10427987
doi: 10.1016/j.omto.2023.07.007
He X, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135(10):713–23.
pubmed: 31951650
pmcid: 7059518
doi: 10.1182/blood.2019002779
Li D, et al. Camel nanobody-based B7–H3 CAR-T cells show high efficacy against large solid tumours. Nat Commun. 2023;14(1):5920.
pubmed: 37739951
pmcid: 10517151
doi: 10.1038/s41467-023-41631-w
Xie YJ, et al. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci. 2019;116(16):7624–31.
pubmed: 30936321
pmcid: 6475367
doi: 10.1073/pnas.1817147116
Chen M, et al. Envafolimab–first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors. Expert Opin Biol Ther. 2022;22(10):1227–32.
pubmed: 36124972
doi: 10.1080/14712598.2022.2125799
Hassanzadeh Eskafi A, et al. Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1/VEGF nanobody in inhibition of angiogenesis. Immunopharmacol Immunotoxicol. 2023;45(2):197–202.
pubmed: 36193665
doi: 10.1080/08923973.2022.2131571
Li B, et al. A PD-L1xCD3 bispecific nanobody as a novel T-cell engager in treating PD-L1 overexpression melanoma. Mol Immunol. 2023;163:20–7.
pubmed: 37722180
doi: 10.1016/j.molimm.2023.09.005
Fan J, et al. A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models. Signal Transduct Target Ther. 2021;6(1):320.
pubmed: 34475375
pmcid: 8413295
doi: 10.1038/s41392-021-00666-5
Toffoli EC, et al. Enhancement of NK cell antitumor effector functions using a bispecific single domain antibody targeting CD16 and the epidermal growth factor receptor. Cancers (Basel). 2021;13(21):5446.
pubmed: 34771609
doi: 10.3390/cancers13215446
Narbona J, et al. Nanobody-Based EGFR-targeting immunotoxins for colorectal cancer treatment. Biomolecules. 2023; 13(7).
Valenzuela-Nieto G, et al. Nanobodies: COVID-19 and future perspectives. Front Drug Discovery. 2022;2: 927164.
doi: 10.3389/fddsv.2022.927164
Aria H, et al. Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: a systematic review. Anal Biochem. 2022;640: 114546.
pubmed: 34995616
pmcid: 8730734
doi: 10.1016/j.ab.2022.114546
Wu D, et al. A naive phage display library-derived nanobody neutralizes SARS-CoV-2 and three variants of concern. Int J Nanomedicine. 2023;18:5781–95.
pubmed: 37869063
pmcid: 10588750
doi: 10.2147/IJN.S427990
Yao H, et al. A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses, including all major Omicron strains. MedComm. 2023;4(6): e397.
pubmed: 37901798
pmcid: 10600506
doi: 10.1002/mco2.397
Ma H, et al. Potent neutralization of SARS-CoV-2 by hetero-bivalent alpaca nanobodies targeting the spike receptor-binding domain. J Virol. 2021;95(10):10.
doi: 10.1128/JVI.02438-20
Gai J, et al. A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential. MedComm. 2021;2(1):101–13.
pubmed: 33821254
pmcid: 8013425
doi: 10.1002/mco2.60
Ye G, et al. Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19. J Virol. 2023;97(11):e01448-e1523.
pubmed: 37855638
pmcid: 10688364
doi: 10.1128/jvi.01448-23
Bhattacharya M, et al. Therapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: current update. Int J Biol Macromol. 2023;229:70–80.
pubmed: 36586649
doi: 10.1016/j.ijbiomac.2022.12.284
Gauhar A, et al. Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro. Faseb J. 2021;35(11): e21970.
pubmed: 34637549
doi: 10.1096/fj.202100986RR
Su, Q., et al., Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein. Cells, 2022. 11(21).
Lim H, et al. Single-domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. Biomed Eng Adv. 2022;4:100054.
pubmed: 36158162
pmcid: 9482557
doi: 10.1016/j.bea.2022.100054
Mast FD, et al. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. Elife. 2021;10: e73027.
pubmed: 34874007
pmcid: 8651292
doi: 10.7554/eLife.73027
Cunha-Santos C, et al. Inhibition of HIV replication through siRNA carried by CXCR4-targeted chimeric nanobody. Cell Mol Life Sci. 2020;77:2859–70.
pubmed: 31641784
doi: 10.1007/s00018-019-03334-8
Cunningham S, et al. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(1):21–32.
pubmed: 33002427
doi: 10.1016/S2213-2600(20)30320-9
Broadbent L. et al. Comparative therapeutic potential of ALX-0171 and palivizumab against respiratory syncytial virus clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures. Antimicrob Agents Chemother, 2020; 64(2).
Mei Y, et al. Research progress and applications of nanobody in human infectious diseases. Front Pharmacol. 2022;13: 963978.
pubmed: 36034845
pmcid: 9411660
doi: 10.3389/fphar.2022.963978
Salmen W, et al. A single nanobody neutralizes multiple epochally evolving human noroviruses by modulating capsid plasticity. Nat Commun. 2023;14(1):6516.
pubmed: 37845211
pmcid: 10579229
doi: 10.1038/s41467-023-42146-0
Saunders N, et al. TMPRSS2 is a functional receptor for human coronavirus HKU1. Nature. 2023;624:207.
pubmed: 37879362
pmcid: 11331971
doi: 10.1038/s41586-023-06761-7
Dietrich MH, et al. Nanobodies against Pfs230 block Plasmodium falciparum transmission. Biochem J. 2022;479(24):2529–46.
pubmed: 36520108
doi: 10.1042/BCJ20220554
Lin J, et al. Characterization and applications of nanobodies against Pseudomonas aeruginosa Exotoxin A selected from single alpaca B cells. Biotechnol Biotechnol Equip. 2020;34(1):1028–37.
doi: 10.1080/13102818.2020.1817782
Wouters Y, et al. Identification and in vivo characterization of a brain-penetrating nanobody. Fluids Barriers CNS. 2020;17(1):62.
pubmed: 33054787
pmcid: 7556960
doi: 10.1186/s12987-020-00226-z
Marino M, Holt MG. AAV vector-mediated antibody delivery (A-MAD) in the central nervous system. Front Neurol. 2022;13: 870799.
pubmed: 35493843
pmcid: 9039256
doi: 10.3389/fneur.2022.870799
Marino M, et al. AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer’s disease model. EMBO Mol Med. 2022;14(4): e09824.
pubmed: 35352880
pmcid: 8988209
doi: 10.15252/emmm.201809824
Bélanger K, et al. Single-domain antibodies as therapeutic and imaging agents for the treatment of CNS diseases. Antibodies. 2019;8(2):27.
pubmed: 31544833
pmcid: 6640712
doi: 10.3390/antib8020027
Zhao L, et al. Multivalent nanobody conjugate with rigid, reactive oxygen species scavenging scaffold for multi-target therapy of Alzheimer’s disease. Adv Mater. 2023;35(17): e2210879.
pubmed: 36786375
doi: 10.1002/adma.202210879
Kang MS, et al. Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer’s disease therapeutic. J Cereb Blood Flow Metab. 2022;42(5):788–801.
pubmed: 34378436
doi: 10.1177/0271678X211035625
Abskharon R, et al. Structure-based design of nanobodies that inhibit seeding of Alzheimer’s patient–extracted tau fibrils. Proc Natl Acad Sci. 2023;120(41): e2300258120.
pubmed: 37801475
pmcid: 10576031
doi: 10.1073/pnas.2300258120
Danis C, et al. Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment. Mol Ther. 2022;30(4):1484–99.
pubmed: 35007758
pmcid: 9077319
doi: 10.1016/j.ymthe.2022.01.009
Monti G, et al. Epitope mapping of nanobodies binding the Alzheimer’s disease receptor SORLA. J Biotechnol. 2023;375:17–27.
pubmed: 37634829
doi: 10.1016/j.jbiotec.2023.08.005
Leemans M, et al. Allosteric modulation of the GTPase activity of a bacterial LRRK2 homolog by conformation-specific Nanobodies. Biochem J. 2020;477(7):1203–18.
pubmed: 32167135
doi: 10.1042/BCJ20190843
Singh RK, et al. Nanobodies as allosteric modulators of Parkinson’s disease–associated LRRK2. Proc Natl Acad Sci. 2022;119(9): e2112712119.
pubmed: 35217606
pmcid: 8892280
doi: 10.1073/pnas.2112712119
Butler YR, et al. alpha-Synuclein fibril-specific nanobody reduces prion-like alpha-synuclein spreading in mice. Nat Commun. 2022;13(1):4060.
pubmed: 35853942
pmcid: 9296447
doi: 10.1038/s41467-022-31787-2
Hmila I, et al. Novel engineered nanobodies specific for N-terminal region of alpha-synuclein recognize Lewy-body pathology and inhibit in-vitro seeded aggregation and toxicity. FEBS J. 2022;289(15):4657–73.
pubmed: 35090199
pmcid: 9545584
doi: 10.1111/febs.16376
Kumar MS, et al. Anti-SOD1 nanobodies that stabilize misfolded SOD1 proteins also promote neurite outgrowth in mutant SOD1 human neurons. Int J Mol Sci. 2022;23(24):16013.
pubmed: 36555655
pmcid: 9784173
doi: 10.3390/ijms232416013
Gilodi M, et al. Selection and modelling of a new single-domain intrabody against TDP-43. Front Mol Biosci. 2021;8: 773234.
pubmed: 35237655
doi: 10.3389/fmolb.2021.773234
Knoebl P, et al. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020;18(2):479–84.
pubmed: 31691462
doi: 10.1111/jth.14679
Palanques-Pastor T, et al. Effectiveness of caplacizumab nanobody in acquired thrombotic thrombocytopenic purpura refractory to conventional treatment. Acta Haematol. 2022;145(1):72–7.
pubmed: 34352748
doi: 10.1159/000517813
Estcourt LJ. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial). Transfus Med. 2019;29(3):146–8.
pubmed: 31318128
doi: 10.1111/tme.12615
Gavriilaki E, et al. Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data. Front Med (Lausanne). 2023;10:1226114.
pubmed: 37901415
doi: 10.3389/fmed.2023.1226114
Miyakawa Y, et al. The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study. Int J Hematol. 2023;117(3):366–77.
pubmed: 36427162
doi: 10.1007/s12185-022-03495-6
Scully M, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335–46.
pubmed: 30625070
doi: 10.1056/NEJMoa1806311
Scully M, et al. Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: post-HERCULES study. J Thromb Haemost. 2022;20(12):2810–22.
pubmed: 36138517
pmcid: 9827931
doi: 10.1111/jth.15892
Volker LA, et al. Five years of caplacizumab—lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura. J Thromb Haemost. 2023;21(10):2718–25.
pubmed: 37562668
doi: 10.1016/j.jtha.2023.07.027
Arce NA, et al. Activation of von Willebrand factor via mechanical unfolding of its discontinuous autoinhibitory module. Nat Commun. 2021;12(1):2360.
pubmed: 33883551
pmcid: 8060278
doi: 10.1038/s41467-021-22634-x
Lee HT, et al. High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP. Biochem Biophys Res Commun. 2021;567:49–55.
pubmed: 34144500
doi: 10.1016/j.bbrc.2021.06.030
Tanaka Y, et al. Efficacy and safety of anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’without methotrexate co-administration in patients with active rheumatoid arthritis: a 52-week result of phase III, randomised, open-label trial (NATSUZORA trial). Mod Rheumatol. 2023;33(5):875–82.
pubmed: 36201360
doi: 10.1093/mr/roac126
Tanaka Y, et al. Efficacy and safety of the anti-TNF multivalent NANOBODY(R) compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 52-week result of a Phase II/III study (OHZORA trial). Mod Rheumatol. 2023;33(5):883–90.
pubmed: 36197757
doi: 10.1093/mr/roac119
Takeuchi T, et al. Phase II/III results of a trial of anti-tumor necrosis factor multivalent NANOBODY compound ozoralizumab in patients with rheumatoid arthritis. Arthritis Rheumatol. 2022;74(11):1776–85.
pubmed: 35729713
pmcid: 9828347
doi: 10.1002/art.42273
Svecova D, et al. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis. J Am Acad Dermatol. 2019;81(1):196–203.
pubmed: 30926369
doi: 10.1016/j.jaad.2019.03.056
Papp KA, et al. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021;397(10284):1564–75.
pubmed: 33894834
doi: 10.1016/S0140-6736(21)00440-2
Zhou Z, et al. Improved production of anti-FGF-2 nanobody using pichia pastoris and its effect on antiproliferation of keratinocytes and alleviation of psoriasis. Arch Immunol Ther Exp (Warsz). 2023;71(1):20.
pubmed: 37632545
doi: 10.1007/s00005-023-00685-w
Gesiorowski A, et al. Bispecific soluble cytokine receptor-nanobody fusions inhibit Interleukin (IL-)6 trans-signaling and IL-12/23 or tumor necrosis factor (TNF) signaling. J Biol Chem. 2023;299(11): 105343.
pubmed: 37838173
pmcid: 10652096
doi: 10.1016/j.jbc.2023.105343
Lynch JP, et al. Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut. Cell Host Microbe. 2023;31(4):634–49.
pubmed: 37003258
pmcid: 10101937
doi: 10.1016/j.chom.2023.03.007
Liu R, et al. Identification and characterization of a novel nanobody against human CTGF to reveal its antifibrotic effect in an in vitro model of liver fibrosis. Int J Nanomed. 2023;18:5407–22.
doi: 10.2147/IJN.S428430
Van Campenhout R, et al. Nanobody-based pannexin1 channel inhibitors reduce inflammation in acute liver injury. J Nanobiotechnol. 2023;21(1):371.
doi: 10.1186/s12951-023-02137-1
Yao G, et al. Nanobody-functionalized conduit with built-in static mixer for specific elimination of cytokines in hemoperfusion. Acta Biomater. 2023;172:260–71.
pubmed: 37806373
doi: 10.1016/j.actbio.2023.09.050
Ma L, et al. Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma. Respir Res. 2022;23(1):316.
pubmed: 36403040
pmcid: 9675287
doi: 10.1186/s12931-022-02240-1
Bailon Calderon H, et al. Development of nanobodies against hemorrhagic and myotoxic components of bothrops atrox snake venom. Front Immunol. 2020;11:655.
pubmed: 32457735
pmcid: 7224310
doi: 10.3389/fimmu.2020.00655
Wilmes M, et al. Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions. J Neuroinflammation. 2022;19(1):256.
pubmed: 36224611
pmcid: 9559872
doi: 10.1186/s12974-022-02601-z
Struijf EM, et al. Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies. J Biol Chem. 2023;299(8): 104956.
pubmed: 37356719
pmcid: 10374974
doi: 10.1016/j.jbc.2023.104956
Barakat S, et al. Nanobodies as molecular imaging probes. Free Radical Biol Med. 2022;182:260–75.
doi: 10.1016/j.freeradbiomed.2022.02.031
de Beer MA, Giepmans BNG. Nanobody-based probes for subcellular protein identification and visualization. Front Cell Neurosci. 2020;14: 573278.
pubmed: 33240044
pmcid: 7667270
doi: 10.3389/fncel.2020.573278
Qin X, et al. Development of novel-nanobody-based lateral-flow immunochromatographic strip test for rapid detection of recombinant human interferon alpha2b. J Pharm Anal. 2022;12(2):308–16.
pubmed: 35582401
doi: 10.1016/j.jpha.2021.07.003
Glassman PM, et al. Molecularly engineered nanobodies for tunable pharmacokinetics and drug delivery. Bioconjug Chem. 2020;31(4):1144–55.
pubmed: 32167754
pmcid: 7413641
doi: 10.1021/acs.bioconjchem.0c00003
Ji F, et al. Nanobodies: from serendipitous discovery of heavy chain-only antibodies in camelids to a wide range of useful applications. Methods Mol Biol. 2022;2446:3–17.
pubmed: 35157266
doi: 10.1007/978-1-0716-2075-5_1
Zheng F, et al. Applications of nanobodies in brain diseases. Front Immunol. 2022;13:978513.
pubmed: 36426363
pmcid: 9679430
doi: 10.3389/fimmu.2022.978513
Leopold AV, Shcherbakova DM, Verkhusha VV. Fluorescent biosensors for neurotransmission and neuromodulation: engineering and applications. Front Cell Neurosci. 2019;13:474.
pubmed: 31708747
pmcid: 6819510
doi: 10.3389/fncel.2019.00474
Wang W, Yuan J, Jiang C. Applications of nanobodies in plant science and biotechnology. Plant Mol Biol. 2021;105(1–2):43–53.
pubmed: 33037986
doi: 10.1007/s11103-020-01082-z
Zakri AM, et al. Generation and characterization of nanobodies against tomato leaf curl sudan virus. Plant Dis. 2021;105(9):2410–7.
pubmed: 33599515
doi: 10.1094/PDIS-11-20-2407-RE
Gettemans J. Site-specific fluorescent labeling, single-step immunocytochemistry, and delivery of nanobodies into living cells. In: Single-domain antibodies: methods and protocols. Springer; 2022. p. 373–93.
doi: 10.1007/978-1-0716-2075-5_19
Farrants H, et al. Chemogenetic control of nanobodies. Nat Methods. 2020;17(3):279–82.
pubmed: 32066961
doi: 10.1038/s41592-020-0746-7
Gu K, et al. Development of nanobody-horseradish peroxidase-based sandwich ELISA to detect Salmonella Enteritidis in milk and in vivo colonization in chicken. J Nanobiotechnology. 2022;20(1):167.
pubmed: 35361208
pmcid: 8973953
doi: 10.1186/s12951-022-01376-y
Wang Y, et al. Enhancing oriented immobilization efficiency: a one-for-two organism-bispecific nanobody scaffold for highly sensitive detection of foodborne pathogens. Anal Chem. 2023.
Liu ML, et al. A bispecific nanobody with high sensitivity/efficiency for simultaneous determination of carbaryl and its metabolite 1-naphthol in the soil and rice samples. Environ Pollut. 2023;335: 122265.
pubmed: 37517641
pmcid: 10529271
doi: 10.1016/j.envpol.2023.122265
De Greve H, et al. Simplified monomeric VHH-Fc antibodies provide new opportunities for passive immunization. Curr Opin Biotechnol. 2020;61:96–101.
pubmed: 31810049
doi: 10.1016/j.copbio.2019.11.006
De Munter S, et al. Rapid and effective generation of nanobody based CARs using PCR and gibson assembly. Int J Mol Sci. 2020;21(3):883.
pubmed: 32019116
pmcid: 7037261
doi: 10.3390/ijms21030883
Hassani M, et al. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer. J Cell Biochem. 2019;120(6):10787–95.
pubmed: 30672018
doi: 10.1002/jcb.28370
Yang EY, Shah K. Nanobodies: next generation of cancer diagnostics and therapeutics. Front Oncol. 2020;10:1182.
pubmed: 32793488
pmcid: 7390931
doi: 10.3389/fonc.2020.01182
Bocancia-Mateescu L-A, et al. Nanobodies as diagnostic and therapeutic tools for cardiovascular diseases (CVDs). Pharmaceuticals. 2023;16(6):863.
pubmed: 37375810
pmcid: 10301117
doi: 10.3390/ph16060863
Harmsen MM, et al. Single-domain antibody multimers for detection of botulinum neurotoxin serotypes C, D, and their mosaics in endopep-MS. Toxins. 2023;15(9):573.
pubmed: 37755999
pmcid: 10535107
doi: 10.3390/toxins15090573
Xavier C, et al. Synthesis, preclinical validation, dosimetry, and toxicity of <sup>68</sup>Ga-NOTA-Anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med. 2013;54(5):776–84.
pubmed: 23487015
doi: 10.2967/jnumed.112.111021
Hrynchak I, et al. Nanobody-based theranostic agents for HER2-positive breast cancer: radiolabeling strategies. Int J Mol Sci. 2021;22(19):10745.
pubmed: 34639086
pmcid: 8509594
doi: 10.3390/ijms221910745
Maeda R, et al. A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. Commun Biol. 2022;5(1):669.
pubmed: 35794202
pmcid: 9257560
doi: 10.1038/s42003-022-03630-3
Kordus SL, et al. Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo. PLoS Pathog. 2023;19(10):e1011496.
pubmed: 37871122
pmcid: 10621975
doi: 10.1371/journal.ppat.1011496
Hu Y, et al. Identification of serum ferritin-specific nanobodies and development towards a diagnostic immunoassay. Biomolecules. 2022;12(8):1080.
pubmed: 36008974
pmcid: 9406126
doi: 10.3390/biom12081080
Arce LP, et al. A multispecies competitive nanobody-based ELISA for the detection of antibodies against hepatitis E virus. Sci Rep. 2023;13(1):15448.
pubmed: 37723180
pmcid: 10507121
doi: 10.1038/s41598-023-41955-z
Wang W, et al. Highly sensitive detection of CTLA-4-positive T-cell subgroups based on nanobody and fluorescent carbon quantum dots. Oncol Lett. 2019;18(1):109–16.
pubmed: 31289479
pmcid: 6540141
He J, et al. Construction of immunomagnetic particles with high stability in stringent conditions by site-directed immobilization of multivalent nanobodies onto bacterial magnetic particles for the environmental detection of tetrabromobisphenol-A. Anal Chem. 2020;92(1):1114–21.
pubmed: 31763820
doi: 10.1021/acs.analchem.9b04177
Morales-Yanez F, et al. Fast one-step ultrasensitive detection of toxocara canis antigens by a nanobody-based electrochemical magnetosensor. Anal Chem. 2019;91(18):11582–8.
pubmed: 31429269
doi: 10.1021/acs.analchem.9b01687
Sánchez-Salcedo R, et al. Comparing nanobody and aptamer-based capacitive sensing for detection of interleukin-6 (IL-6) at physiologically relevant levels. Anal Bioanalytical Chem. 2023;415:7035.
doi: 10.1007/s00216-023-04973-4
Ghumra DP, et al. Rapid direct detection of SARS-CoV-2 aerosols in exhaled breath at the point of care. ACS sensors. 2023;8(8):3023–31.
pubmed: 37498298
pmcid: 10463275
doi: 10.1021/acssensors.3c00512
Guo K, et al. Rapid single-molecule detection of COVID-19 and MERS antigens via nanobody-functionalized organic electrochemical transistors. Nat Biomed Eng. 2021;5(7):666–77.
pubmed: 34031558
doi: 10.1038/s41551-021-00734-9
Keyaerts M, et al. Phase II trial of HER2-PET/CT using 68Ga-anti-HER2 VHH1 for characterization of HER2 presence in brain metastases of breast cancer patients. Ann Oncol. 2019;30:iii25–6.
doi: 10.1093/annonc/mdz095.081
Ma J, et al. CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin. Biomater Res. 2022;26(1):64.
pubmed: 36435809
pmcid: 9701387
doi: 10.1186/s40824-022-00312-3
Li L, et al. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking. Theranostics. 2022;12(12):5551–63.
pubmed: 35910795
pmcid: 9330517
doi: 10.7150/thno.74154
Li L, et al. Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga] Ga-nanobody: from bench to bedside. Eur J Nucl Med Mol Imaging. 2023;50:3735.
pubmed: 37382662
doi: 10.1007/s00259-023-06313-1
Altunay B, et al. 99mTc-labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types. Eur J Nucl Med Mol Imaging. 2023;50(4):1005–13.
pubmed: 36482076
doi: 10.1007/s00259-022-06066-3
Lecocq Q, et al. Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer. EJNMMI Res. 2021;11(1):115.
pubmed: 34727262
pmcid: 8563901
doi: 10.1186/s13550-021-00857-9
Zeven K, et al. Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT. Front Immunol. 2023;14:1268900.
pubmed: 37799715
pmcid: 10548220
doi: 10.3389/fimmu.2023.1268900
Fayn S, et al. Site-specifically conjugated single-domain antibody successfully identifies glypican-3-expressing liver cancer by immuno-PET. J Nucl Med. 2023;64(7):1017–23.
pubmed: 36997331
pmcid: 10315705
doi: 10.2967/jnumed.122.265171
Wang Y, et al. Pilot study of a novel nanobody (68) Ga-NODAGA-SNA006 for instant PET imaging of CD8(+) T cells. Eur J Nucl Med Mol Imaging. 2022;49(13):4394–405.
pubmed: 35829748
doi: 10.1007/s00259-022-05903-9
Zheng F, et al. NIRF-molecular imaging with synovial macrophages-targeting Vsig4 nanobody for disease monitoring in a mouse model of arthritis. Int J Mol Sci. 2019;20(13):3347.
pubmed: 31288389
pmcid: 6651725
doi: 10.3390/ijms20133347
Hughes D, et al. SPECT/CT using [99mTc]-labeled anti-programmed death-ligand 1 (PD-L1) single-domain antibody (NM-01) to predict response to immune checkpoint inhibition in non-small cell lung cancer: preliminary results from the PD-L1 Expression in Cancer (PECan) study. 2022, Soc Nuclear Med.
Yang Y, et al. Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody. EJNMMI Res. 2021;11(1):113.
pubmed: 34718889
pmcid: 8557220
doi: 10.1186/s13550-021-00854-y
Lv G, et al. PET imaging of tumor PD-L1 expression with a highly specific nonblocking single-domain antibody. J Nucl Med. 2020;61(1):117–22.
pubmed: 31253743
pmcid: 6954462
doi: 10.2967/jnumed.119.226712
Xavier C, et al. Clinical translation of [(68)Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT imaging of protumorigenic macrophages. Mol Imaging Biol. 2019;21(5):898–906.
pubmed: 30671739
doi: 10.1007/s11307-018-01302-5
Varasteh Z, et al. Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 68 Ga-NOTA-anti-MMR nanobody: non-invasive imaging of atherosclerotic plaques. EJNMMI Res. 2019;9:1–10.
doi: 10.1186/s13550-019-0474-0
Gondry O, et al. Phase I study of [(68)Ga]Ga-Anti-CD206-sdAb for PET/CT assessment of protumorigenic macrophage presence in solid tumors (MMR Phase I). J Nucl Med. 2023;64(9):1378–84.
pubmed: 37474271
pmcid: 10478821
doi: 10.2967/jnumed.122.264853
Xing Y, et al. Early phase I study of a (99m)Tc-labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small cell lung cancer. J Nucl Med. 2019;60(9):1213–20.
pubmed: 30796165
pmcid: 6735283
doi: 10.2967/jnumed.118.224170
Zhou Z, et al. Labeling single domain antibody fragments with fluorine-18 using 2,3,5,6-tetrafluorophenyl 6-[(18)F]Fluoronicotinate resulting in high tumor-to-kidney ratios. Mol Pharm. 2019;16(1):214–26.
pubmed: 30427188
doi: 10.1021/acs.molpharmaceut.8b00951
Ertveldt T, et al. Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8(+) T cell and iNKT cell activating mRNA vaccine. Theranostics. 2023;13(15):5483–500.
pubmed: 37908728
pmcid: 10614673
doi: 10.7150/thno.85106
Pant K, et al. Active targeting of dendritic polyglycerols for diagnostic cancer imaging. Small. 2020;16(7): e1905013.
pubmed: 31880080
doi: 10.1002/smll.201905013
Montemagno C, et al. 99mTc-A1 as a novel imaging agent targeting mesothelin-expressing pancreatic ductal adenocarcinoma. Cancers. 2019;11(10):1531.
pubmed: 31658755
pmcid: 6827014
doi: 10.3390/cancers11101531
Benloucif A, et al. Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies. Front Immunol. 2023;14:1200652.
pubmed: 37388728
pmcid: 10303918
doi: 10.3389/fimmu.2023.1200652
Broos K, et al. Evaluating a single domain antibody targeting human PD-L1 as a nuclear imaging and therapeutic agent. Cancers. 2019;11(6):872.
pubmed: 31234464
pmcid: 6628009
doi: 10.3390/cancers11060872
Senders ML, et al. Nanobody-facilitated multiparametric PET/MRI phenotyping of atherosclerosis. JACC Cardiovasc Imaging. 2019;12(10):2015–26.
pubmed: 30343086
doi: 10.1016/j.jcmg.2018.07.027
Jailkhani N, et al. Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix. Proc Natl Acad Sci U S A. 2019;116(28):14181–90.
pubmed: 31068469
pmcid: 6628802
doi: 10.1073/pnas.1817442116
Steyaert J, Kobilka BK. Nanobody stabilization of G protein-coupled receptor conformational states. Curr Opin Struct Biol. 2011;21(4):567–72.
pubmed: 21782416
pmcid: 3166880
doi: 10.1016/j.sbi.2011.06.011
Uchanski T, Pardon E, Steyaert J. Nanobodies to study protein conformational states. Curr Opin Struct Biol. 2020;60:117–23.
pubmed: 32036243
doi: 10.1016/j.sbi.2020.01.003
Frecot DI, Froehlich T, Rothbauer U. 30 years of nanobodies–an ongoing success story of small binders in biological research. J Cell Sci. 2023;136(21):jcs261395.
pubmed: 37937477
doi: 10.1242/jcs.261395
Dmitriev OY, Lutsenko S, Muyldermans S. Nanobodies as probes for protein dynamics in vitro and in cells. J Biol Chem. 2016;291(8):3767–75.
pubmed: 26677230
doi: 10.1074/jbc.R115.679811
Limbocker R, et al. Rationally designed antibodies as research tools to study the structure–toxicity relationship of amyloid-β oligomers. Int J Mol Sci. 2020;21(12):4542.
pubmed: 32630615
pmcid: 7352524
doi: 10.3390/ijms21124542
Harmansa S, et al. A nanobody-based toolset to investigate the role of protein localization and dispersal in Drosophila. Elife. 2017; 6.
Bothma JP, et al. LlamaTags: a versatile tool to image transcription factor dynamics in live embryos. Cell. 2018;173(7):1810–22.
pubmed: 29754814
pmcid: 6003873
doi: 10.1016/j.cell.2018.03.069
Loreau V, et al. A nanobody toolbox to investigate localisation and dynamics of Drosophila titins and other key sarcomeric proteins. Elife. 2023; 12.
Tang H, Gao Y, Han J. Application progress of the single domain antibody in medicine. Int J Mol Sci. 2023;24(4):4176.
pubmed: 36835588
pmcid: 9967291
doi: 10.3390/ijms24044176
Yu D, et al. Optogenetic activation of intracellular antibodies for direct modulation of endogenous proteins. Nat Methods. 2019;16(11):1095–100.
pubmed: 31611691
doi: 10.1038/s41592-019-0592-7
Pomeranz L, et al. Magnetogenetic cell activation using endogenous ferritin. bioRxiv, 2023.
Katz HE. Antigen sensing via nanobody-coated transistors. Nat Biomed Eng. 2021;5(7):639–40.
pubmed: 34272521
doi: 10.1038/s41551-021-00765-2
Koklu A, et al. Convection driven ultrarapid protein detection via nanobody-functionalized organic electrochemical transistors. Adv Mater. 2022;34(35): e2202972.
pubmed: 35772173
doi: 10.1002/adma.202202972
Zhang X, et al. Specific detection of proteins by a nanobody-functionalized nanopore sensor. ACS Nano. 2023;17(10):9167–77.
pubmed: 37127291
pmcid: 10184537
doi: 10.1021/acsnano.2c12733
Hirao A, et al. Design of single-domain VHH antibodies to increase the binding activity in SPR amine coupling. Biochem Biophys Res Commun. 2023;663:54–60.
pubmed: 37119766
doi: 10.1016/j.bbrc.2023.04.048
Kao KS, et al. Synthetic nanobodies as tools to distinguish IgG Fc glycoforms. Proc Natl Acad Sci. 2022;119(48): e2212658119.
pubmed: 36409896
pmcid: 9860306
doi: 10.1073/pnas.2212658119
Xi X, et al. A novel shark single-domain antibody targeting OGT as a tool for detection and intracellular localization. Front Immunol. 2023;14:1062656.
pubmed: 36855630
pmcid: 9968394
doi: 10.3389/fimmu.2023.1062656
Jailkhani N, et al. Proteomic profiling of extracellular matrix components from patient metastases identifies consistently elevated proteins for developing nanobodies that target primary tumors and metastases. Can Res. 2023;83(12):2052–65.
doi: 10.1158/0008-5472.CAN-22-1532
Liu S, et al. Improved sensitivity of the anti-microcystin-LR ELISA using phage-displayed alpha-type anti-idiotypic nanobody. Anal Biochem. 2023;664: 115030.
pubmed: 36572217
doi: 10.1016/j.ab.2022.115030
Nguyen-Duc T, et al. Nanobody®-based chromatin immunoprecipitation/micro-array analysis for genome-wide identification of transcription factor DNA binding sites. Nucleic Acids Res. 2013;41(5):e59–e59.
pubmed: 23275538
doi: 10.1093/nar/gks1342
Momin N, et al. Maximizing response to intratumoral immunotherapy in mice by tuning local retention. Nat Commun. 2022;13(1):109.
pubmed: 35013154
pmcid: 8748612
doi: 10.1038/s41467-021-27390-6
Blanco-Toribio A, et al. Direct injection of functional single-domain antibodies from E. coli into human cells. PLoS ONE. 2010;5(12):e15227.
pubmed: 21170340
pmcid: 2999559
doi: 10.1371/journal.pone.0015227
Lutz EA, et al. Intratumoral nanobody-IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice. PNAS Nexus. 2022;1(5):pgac244.
pubmed: 36712341
pmcid: 9802395
doi: 10.1093/pnasnexus/pgac244
Khaleghi S, Rahbarizadeh F, Nikkhoi SK. Anti-HER2 VHH targeted fluorescent liposome as bimodal nanoparticle for drug delivery and optical imaging. Recent Pat Anti-Cancer Drug Discovery. 2021;16(4):552–62.
pubmed: 34365930
doi: 10.2174/1574892816666210806150929
Mesquita BS, et al. The impact of nanobody density on the targeting efficiency of PEGylated liposomes. Int J Mol Sci. 2022;23(23):14974.
pubmed: 36499301
pmcid: 9741042
doi: 10.3390/ijms232314974
Yin W, et al. BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFRT790M mutation. Theranostics. 2020;10(14):6122.
pubmed: 32483443
pmcid: 7255027
doi: 10.7150/thno.42234
Pham TC, et al. Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery. J Extracell Vesicles. 2021;10(4): e12057.
pubmed: 33643546
pmcid: 7886705
doi: 10.1002/jev2.12057
Zhu S, et al. A nanobody-mediated virus-targeting drug delivery platform for the central nervous system viral disease therapy. Microbiol Spectr. 2021;9(3): e0148721.
pubmed: 34817277
doi: 10.1128/Spectrum.01487-21
Malik JA, et al. Nano-drug delivery system: a promising approach against breast cancer. Ther Deliv. 2023;14(5):357–81.
pubmed: 37431741
doi: 10.4155/tde-2023-0020
Banihashemi SR, et al. Liposome-based nanocarriers loaded with anthrax lethal factor and armed with anti-CD19 VHH for effectively inhibiting MAPK pathway in B cells. Int Immunopharmacol. 2021;100: 107927.
pubmed: 34500284
doi: 10.1016/j.intimp.2021.107927
Awad RM, et al. Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade. Mol Ther Methods Clin Dev. 2021;22:172–82.
pubmed: 34485603
pmcid: 8397838
doi: 10.1016/j.omtm.2021.05.017
Silva-Pilipich N, et al. Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses. Cancer Lett. 2023;561: 216139.
pubmed: 37001752
doi: 10.1016/j.canlet.2023.216139
Yuki Y, et al. Lactobacilli as a vector for delivery of nanobodies against norovirus infection. Pharmaceutics. 2023;15(1):63.
doi: 10.3390/pharmaceutics15010063
Gangaiah D, et al. Recombinant Limosilactobacillus (Lactobacillus) delivering nanobodies against Clostridium perfringens NetB and alpha toxin confers potential protection from necrotic enteritis. Microbiologyopen. 2022;11(2): e1270.
pubmed: 35478283
pmcid: 8924699
doi: 10.1002/mbo3.1270
Zhang L, et al. Nanobody Nb6 fused with porcine IgG Fc as the delivering tag to inhibit porcine reproductive and respiratory syndrome virus replication in porcine alveolar macrophages. Vet Res. 2021;52:1–14.
doi: 10.1186/s13567-020-00868-9
Hamann MV, et al. Improved targeting of human CD4+ T cells by nanobody-modified AAV2 gene therapy vectors. PLoS ONE. 2021;16(12): e0261269.
pubmed: 34928979
pmcid: 8687595
doi: 10.1371/journal.pone.0261269
Lee M, et al. Advanced genetic engineering to achieve in vivo targeting of adenovirus utilizing camelid single domain antibody. J Control Release. 2021;334:106–13.
pubmed: 33872627
pmcid: 10292108
doi: 10.1016/j.jconrel.2021.04.009
Morrison C. Nanobody approval gives domain antibodies a boost. Nat Rev Drug Discov. 2019;18(7):485–7.
pubmed: 31267082
doi: 10.1038/d41573-019-00104-w
Hollifield AL, Arnall JR, Moore DC. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura. Am J Health Syst Pharm. 2020;77(15):1201–7.
pubmed: 32588878
doi: 10.1093/ajhp/zxaa151
Mullard A. FDA approves second BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov. 2022;21(4):249.
pubmed: 35277679
Keam SJ. Ozoralizumab: first approval. Drugs. 2023;83(1):87–92.
pubmed: 36509938
doi: 10.1007/s40265-022-01821-0
Fang Y, et al. DR30303, a SMART-VHHBody powered anti-CLDN18. 2 VHH-Fc with enhanced ADCC activity for the treatment of gastric and pancreatic cancers. Cancer Res. 2022;82(12_Supplement):2857–2857.
doi: 10.1158/1538-7445.AM2022-2857
Yamamoto N, et al. Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2023;91(6):469–80.
pubmed: 37140602
doi: 10.1007/s00280-023-04527-6
Shimizu T, et al. Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors. Invest New Drugs. 2022;40(5):1021–31.
pubmed: 35932387
doi: 10.1007/s10637-022-01287-7
Li J, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14(1):95.
pubmed: 34154614
pmcid: 8218452
doi: 10.1186/s13045-021-01095-1
Papadopoulos KP, et al. First-in-human phase I study of envafolimab, a novel subcutaneous single-domain anti-PD-L1 antibody, in patients with advanced solid tumors. Oncologist. 2021;26(9):e1514–25.
pubmed: 33973293
pmcid: 8417852
doi: 10.1002/onco.13817
D’Huyvetter M, et al. Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients. J Nucl Med. 2021;62(8):1097–105.
pubmed: 33277400
doi: 10.2967/jnumed.120.255679
Ramlau R, et al. P2. 06-006 Phase I/II dose escalation study of L-DOS47 as a monotherapy in non-squamous non-small cell lung cancer patients: topic: phase I/II trials. J Thoracic Oncol. 2017;12(1):S1071–2.
doi: 10.1016/j.jtho.2016.11.1499
Piha-Paul S, et al. A phase 1, open-label, dose-escalation study of L-DOS47 in combination with pemetrexed plus carboplatin in patients with stage IV recurrent or metastatic nonsquamous NSCLC. JTO Clin Res Rep. 2022;3(11): 100408.
pubmed: 36268537
pmcid: 9576893
Kater AP, et al. Lava-051, a novel bispecific gamma-delta T-cell engager (Gammabody), in relapsed/refractory MM and CLL: pharmacodynamic and early clinical data. Blood. 2022;140(Supplement 1):4608–9.
doi: 10.1182/blood-2022-166851
Mehra N, et al. Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC). 2023, American Society of Clinical Oncology.
Martin T, et al. Updated results from CARTITUDE-1: phase 1b/2Study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Blood. 2021;138:549.
doi: 10.1182/blood-2021-146060
Berdeja JG, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–24.
pubmed: 34175021
doi: 10.1016/S0140-6736(21)00933-8
Zhao WH, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022;15(1):86.
pubmed: 35794616
pmcid: 9261106
doi: 10.1186/s13045-022-01301-8
van de Donk N, et al. B07: safety and efficacy of ciltacabtagene autoleucel, a chimeric antigen receptor t-cell therapy directed against b-cell maturation antigen in patients with multiple myeloma and early relapse after initial therapy: cartitude-2 results. HemaSphere. 2022;6:9–10.
pmcid: 9012122
doi: 10.1097/01.HS9.0000829568.10814.bc
Einsele H, et al. P08: CARTITUDE-2 UPDATE: Ciltacabtagene autoleucel, a b-cell maturation antigen–directed chimeric antigen receptor T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1–3 prior lines of therapy. Hemasphere. 2022;6:15.
pmcid: 9012124
doi: 10.1097/01.HS9.0000829604.35383.e8
Cohen YC, et al. Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a b-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1–3 prior lines of therapy: Updated results from CARTITUDE-2. Blood. 2021;138:3866.
doi: 10.1182/blood-2021-146072
Agha ME, et al. S185: CARTITUDE-2 cohort B: updated clinical data and biological correlative analyses of ciltacabtagene autoleucel in patients with multiple myeloma and early relapse after initial therapy. HemaSphere. 2022;6:86–7.
doi: 10.1097/01.HS9.0000843632.57974.e8
Brussel, U.Z. Quantification of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Metastasis of Breast Carcinoma Patients and Assessment of Repeatability (VUBAR)—Pilot Study. ClinicalTrials.gov identifier: NCT03924466. September 10, 2024]; Available from: https://clinicaltrials.gov/study/NCT03924466?a=3 .
Alexion Pharmaceuticals, I., A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis. ClinicalTrial.gov Identifier: NCT05556096.
Muyldermans S. Applications of nanobodies. Annu Rev Anim Biosci. 2021;9:401–21.
pubmed: 33233943
doi: 10.1146/annurev-animal-021419-083831
Sun S, et al. Nanobody: a small antibody with big implications for tumor therapeutic strategy. Int J Nanomedicine. 2021;16:2337–56.
pubmed: 33790553
pmcid: 7997558
doi: 10.2147/IJN.S297631
Ackaert C, et al. Immunogenicity risk profile of nanobodies. Front Immunol. 2021;12: 632687.
pubmed: 33767701
pmcid: 7985456
doi: 10.3389/fimmu.2021.632687
Rossotti MA, et al. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2022;289(14):4304–27.
pubmed: 33751827
doi: 10.1111/febs.15809
van Leeuwen FW, et al. Trending: radioactive and fluorescent bimodal/hybrid tracers as multiplexing solutions for surgical guidance. J Nucl Med. 2020;61(1):13–9.
pubmed: 31712326
doi: 10.2967/jnumed.119.228684
Messer A, Butler DC. Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders. Neurobiol Dis. 2020;134: 104619.
pubmed: 31669671
doi: 10.1016/j.nbd.2019.104619
Valdés-Tresanco MS, et al. Structural modeling of nanobodies: a benchmark of state-of-the-art artificial intelligence programs. Molecules. 2023;28(10):3991.
pubmed: 37241731
pmcid: 10220908
doi: 10.3390/molecules28103991
Yang X, et al. Opportunities and challenges for antibodies against intracellular antigens. Theranostics. 2019;9(25):7792–806.
pubmed: 31695801
pmcid: 6831482
doi: 10.7150/thno.35486
Awad RM, et al. Emerging applications of nanobodies in cancer therapy. Int Rev Cell Mol Biol. 2022;369:143–99.
pubmed: 35777863
doi: 10.1016/bs.ircmb.2022.03.010
Wouters Y, et al. VHHs as tools for therapeutic protein delivery to the central nervous system. Fluids Barriers CNS. 2022;19(1):1–13.
doi: 10.1186/s12987-022-00374-4
Al-Numair NS, et al. Camels’ biological fluids contained nanobodies: promising avenue in cancer therapy. Cancer Cell Int. 2022;22(1):279.
pubmed: 36071488
pmcid: 9449263
doi: 10.1186/s12935-022-02696-7
Lowden MJ, et al. Applications of high-throughput DNA sequencing to single-domain antibody discovery and engineering. Methods Mol Biol. 2023;2702:489–540.
pubmed: 37679637
doi: 10.1007/978-1-0716-3381-6_26
Arras P, et al. AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study. Front Mol Biosci. 2023;10:1249247.
pubmed: 37842638
pmcid: 10575757
doi: 10.3389/fmolb.2023.1249247
Laustsen AH, et al. Animal immunization, in vitro display technologies, and machine learning for antibody discovery. Trends Biotechnol. 2021;39(12):1263–73.
pubmed: 33775449
doi: 10.1016/j.tibtech.2021.03.003
Rabbitts T. Intracellular antibodies for drug discovery and as drugs of the future. Antibodies. 2023;12(1):24.
pubmed: 36975371
pmcid: 10044824
doi: 10.3390/antib12010024
Jiang X, et al. Shark IgNAR: the next broad application antibody in clinical diagnoses and tumor therapies? Mar Drugs. 2023;21(9):496.
pubmed: 37755109
pmcid: 10532743
doi: 10.3390/md21090496
Hamers-Casterman C, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446–8.
pubmed: 8502296
doi: 10.1038/363446a0
Desmyter A, et al. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat Struct Biol. 1996;3(9):803–11.
pubmed: 8784355
doi: 10.1038/nsb0996-803
Huo J, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020;27(9):846–54.
pubmed: 32661423
doi: 10.1038/s41594-020-0469-6
Arbabi-Ghahroudi M. Camelid single-domain antibodies: historical perspective and future outlook. Front Immunol. 2017;8:1589.
pubmed: 29209322
pmcid: 5701970
doi: 10.3389/fimmu.2017.01589